Skip to content

Aclaris Therapeutics

US · ACRS #3750 by market cap Listed 2015
3.38 -0.02 -0.71%
Live - 5344 symbols - heartbeat 246s ago · 2026-10-08 10:00
Pre-market 3.44 +1.11%
After-hours 3.46 +1.76%
Overnight 3.39 -0.29%
Market cap
496.94M
P/B
3.99
EPS
-0.53
Reader sentiment Are you bullish or bearish on ACRS?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    LifeSci Capital Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $13
    Market Newswire · 2026/6/2
  • H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $16
    Market Newswire · 2026/8/10
  • Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/8/6
  • Rating change
    Wedbush Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $8
    Market Newswire · 2025/7/31
  • Rating change
    Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $10
    Market Newswire · 2026/4/29
  • LifeSci Capital Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $13
    Market Newswire · 2026/10/2
  • Rating change
    Craig-Hallum Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
    Market Newswire · 2026/1/30
  • Rating change
    Guggenheim Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $12
    Market Newswire · 2026/5/5
  • Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2026/10/7
  • Rating change
    Cantor Fitzgerald Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating
    Market Newswire · 2025/10/15
  • Rating change
    Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
    Market Newswire · 2026/4/16
  • Rating change
    Leerink Partners Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7
    Market Newswire · 2025/10/16
  • Rating change
    Guggenheim Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $12
    Market Newswire · 2026/5/11
  • Rating change
    Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/5/9
  • Rating change
    Wedbush Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $8
    Market Newswire · 2026/1/14
  • Rating change
    Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/5/5
  • Rating change
    H.C. Wainwright Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Cuts Target Price to $16
    Market Newswire · 2025/8/29
  • Rating change
    Oppenheimer Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10
    Market Newswire · 2026/5/8
  • Rating change
    Piper Sandler Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $6
    Market Newswire · 2025/10/15
  • CCORF Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10
    Market Newswire · 2026/9/1

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 10:00:33 · For reference only, not investment advice and not tailored to your situation.